Scott Gottlieb, M.D., a practicing physician, has served in various capacities at the Food and Drug Administration, including senior adviser for medical technology; director of medical policy development; and, most recently, deputy commissioner for medical and scientific affairs. Dr. Gottlieb has also served as a senior policy adviser at the Centers for Medicare & Medicaid Services.
Click here to read Scott’s Medical Innovation blog.
Member, Policy Board, Leukemia and Lymphoma Society, 2012-present
Member, Public Policy Committee, Society for Hospitalist Medicine, 2011-present
Clinical Assistant Professor, New York University School of Medicine, 2011-present
Editorial Board, Food and Drug Law Institute's Policy Forum, 2011-present
Board Member, Keystone Center, 2010-present
Editorial Board Member, Value-Based Cancer Care, 2009-present
Editorial Board Member, Cancer Commons, 2009-present
Deputy Commissioner for Medical and Scientific Affairs, Food and Drug Administration, 2005-2007
Author, Forbes-Gottlieb Medical Technology Report; Columnist Forbes.com, 2004-2005
Director of Medical Policy Development, Food and Drug Administration, 2004
Senior Adviser to the Administrator, Centers for Medicare & Medicaid Services, 2004
Senior Adviser for Medical Technology to the Commissioner, Food and Drug Administration, 2003-2004
Resident Fellow, AEI, 2002-2003 and 2005
Staff Writer, British Medical Journal, 1997-2005
Senior Editor, "Pulse," Journal of the American Medical Association, 1996-2001
Whatever your view on the legal merits of yesterday’s decision by the U.S. Supreme Court, ruling that the discovery of gene sequences is not patentable, the verdict is one more challenge to an industry that’s already on the ropes.
The tragic deaths of 55 Americans and sickening of more than 740, resulting from contaminated steroid injections that were shipped by a disreputable firm in Massachusetts, have rightly focused public attention on a largely unfamiliar, but prominent part of our drug supply chain – the practice of pharmacy compounding.
After a political rebuke over the form’s length, the Department of Health and Human Services has released a streamlined, three-page version of the application to sign up for Obamacare’s financial subsidies. The rub? The government’s new form is going to be an invitation to fraud and abuse.